Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Liso-Cel Generates Responses in R/R Marginal Zone Lymphoma

February 10th 2025

Lisocabtagene maraleucel elicited a statistically significant overall response rate in adult patients with relapsed/refractory MZL.

FDA Grants Fast Track Designation to Amezalpat for Hepatocellular Carcinoma

February 10th 2025

The FDA has granted fast track designation to amezalpat for patients with hepatocellular carcinoma.

Pola-R-CHP Generates Long-Term PFS and DFS Advantages vs R-CHOP in Untreated DLBCL

February 7th 2025

Polatuzumab vedotin plus R-CHP improved PFS and DFS vs R-CHOP at 5 years in previously untreated patients with diffuse large B-cell lymphoma.

KN026 Plus Docetaxel Demonstrates Efficacy in HER2+ Metastatic Breast Cancer

February 7th 2025

KN026 plus docetaxel elicited durable responses and a manageable safety profile in patients with recurrent/metastatic HER2-positive breast cancer.

Venetoclax Elicits Immune Synapse Repair in Chronic Lymphocytic Leukemia

February 7th 2025

Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia.

Advances in RAS-Mutant PDAC Management Emphasize the Importance of Biomarker Testing: With Heinz-Josef Lenz, MD

February 6th 2025

Dr Lenz discusses the prevalence of RAS mutations in PDAC, the importance of biomarker testing, and treatment advances for patients with this disease.

Case Closed: Experts Piece Together the Top Takeaways From the 2025 Gastrointestinal Cancers Symposium

February 6th 2025

Get the inside scoop from Drs Lou, Patel, and Beg on the top takeaways to come out of the 2025 Gastrointestinal Cancers Symposium.

Gemogenovatucel-T Receives FDA RMAT Designation for Advanced HRP Ovarian Cancer

February 5th 2025

The FDA granted RMAT designation to gemogenovatucel-T for maintenance treatment after frontline chemotherapy in advanced HRP ovarian cancer.

How Academia and Industry Intersect to Improve Oncology Research and Patient Care: With D. Ross Camidge, MD, PhD; and Tim Eisen, MB BChir, PhD

February 5th 2025

Drs Camidge and Eisen discuss Dr Eisen's dual career in academia and industry, the importance of aligning academic and clinical strengths, and how industry experience can enhance drug development.

Type II JAK Inhibitor AJ1-11095 Under Phase 1 Investigation in Myelofibrosis

February 5th 2025

AJ1-11095 is being evaluated in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia.

FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer

February 5th 2025

The ACR-368 OncoSignature assay has received breakthrough device designation from the FDA for use in endometrial cancer.

Serplulimab Plus Chemotherapy Wins EU Approval for Treatment-Naive ES-SCLC

February 5th 2025

The European Commission has approved serplulimab in combination with carboplatin and etoposide for the frontline treatment of adult patients with ES-SCLC.

Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized

February 4th 2025

The variety of nonclassical EGFR mutations in NSCLC necessitates the development of unique treatment strategies based on individual mutational profiles.

Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD

February 3rd 2025

Dr Jabbour discusses data that support the continued investigation of olverembatinib in patients with heavily pretreated chronic-phase CML.

Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer

February 2nd 2025

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.

Dr Levy on the Development and Clinical Use of ADCs in NSCLC

February 2nd 2025

Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.

Dr Hales on the Use of Post-Operative Radiotherapy in NSCLC

February 2nd 2025

Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer.

Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC

February 2nd 2025

Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.

Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC

February 1st 2025

Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.

Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC

February 1st 2025

Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.